SINGAPORE, June 11, 2026
DKSH Healthcare and BridgeBio have entered into a strategic distribution and commercialization partnership aimed at expanding future patient access to an innovative transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM) across key Asia-Pacific markets. Under the agreement, DKSH will support regulatory evaluation, distribution, market access, and commercialization activities in Australia, Singapore, South Korea, and Taiwan, leveraging its extensive healthcare infrastructure and regional expertise. The partnership combines BridgeBio’s biotechnology innovation with DKSH Healthcare’s end-to-end commercialization platform, creating a pathway to potentially introduce a new treatment option for patients suffering from ATTR-CM, a progressive and life-threatening cardiovascular disease with significant unmet medical needs.
Strategic Alliance Targets Growing Need in Rare Cardiovascular Disease
The collaboration represents an important milestone for both companies as they seek to address the growing burden of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a serious and progressive condition caused by the accumulation of misfolded transthyretin proteins in the heart, leading to worsening cardiac function, frequent hospitalizations, reduced quality of life, and premature mortality. The transthyretin stabilizer covered under the agreement is designed to treat both wild-type and variant forms of ATTR-CM by stabilizing transthyretin proteins and preventing the formation of harmful amyloid deposits.
While the therapy has demonstrated significant clinical potential internationally, it is not currently approved in Australia, Singapore, South Korea, or Taiwan, making regulatory review and market preparation essential next steps. The agreement positions DKSH to play a critical role in supporting future regulatory submissions and facilitating potential access for eligible patients once approvals are obtained.
DKSH to Deliver End-to-End Commercialization and Market Access Support
Advertisement
Through the partnership, DKSH Healthcare will provide comprehensive services spanning regulatory affairs, medical affairs, market access, launch excellence, distribution logistics, and commercial operations. The company’s integrated healthcare platform and deep understanding of regional healthcare systems are expected to accelerate market readiness and support successful product introduction following regulatory approvals. DKSH has established itself as one of Asia-Pacific’s leading healthcare commercialization partners, operating extensive pharmaceutical and healthcare distribution networks across the region.
By combining these capabilities with BridgeBio’s expertise in developing therapies for genetic diseases, the partnership aims to streamline the path from regulatory review to patient access. Company leadership emphasized that expanding availability of innovative treatments for underserved patient populations remains a central objective of the collaboration, particularly for rare diseases where diagnosis and treatment options are often limited.
Partnership Strengthens Rare Disease Innovation Across Asia-Pacific
The agreement reflects a broader trend of increasing collaboration between biotechnology innovators and specialized commercialization partners to bring advanced therapies into emerging and underserved markets. For BridgeBio, the alliance expands the potential geographic reach of its transthyretin stabilizer while providing access to DKSH’s established healthcare infrastructure and commercial execution capabilities. For DKSH Healthcare, the partnership aligns with its strategic vision of strengthening its presence in high-value specialty therapeutics and rare disease markets. Industry experts continue to recognize ATTR-CM as a significantly underdiagnosed condition despite growing awareness and advances in diagnostic technologies.
As healthcare systems improve identification of affected patients, demand for effective disease-modifying therapies is expected to rise substantially. If approved across the covered territories, the transthyretin stabilizer could offer an important new treatment option capable of reducing cardiovascular-related hospitalizations and mortality while improving quality of life for patients living with ATTR-CM. The collaboration therefore represents not only a commercial opportunity but also a meaningful effort to expand access to innovative cardiovascular therapies across Asia-Pacific healthcare markets.
Source: DKSH Healthcare, BridgeBio press release
